-
Cabotegravir, sold
under the
brand name
Vocabria among others, is a
antiretroviral medication used for the
treatment of HIV/AIDS. It is
available in the...
-
Cabotegravir/rilpivirine, sold
under the
brand name Cabenuva, is a co-packaged
antiretroviral medication for the
treatment of HIV/AIDS. It
contains cabotegravir...
- risk
through receptive ****l ****. In
December 2021, the FDA
approved cabotegravir (Apretude),
which is an
injectable form of PrEP
manufactured by ViiV...
- In the
European Union,
rilpivirine is
approved in
combination with
cabotegravir for
maintenance treatment of
adults who have
undetectable HIV levels...
- [betterĀ sourceĀ needed]
Cabotegravir,
developed by ViiV Healthcare, was
approved in
conjunction with
rilpivirine by the FDA in
January 2021 (
cabotegravir/rilpivirine)...
- for two new
antiretroviral (ARV) medicines,
rilpivirine (Rekambys) and
cabotegravir (Vocabria), to be used
together for the
treatment of
people with human...
-
strand transfer inhibitors (INSTIs):
dolutegravir (brand name Tivicay)
cabotegravir (brand
names Apretude [as a
single agent indicated for PrEP]; and Vocabria/Cabenuva...
-
whether injectable cabotegravir could be used for PrEP in
people at
greater risk of
acquiring HIV. The
study showed that
cabotegravir was safe and well-tolerated...
- &. "Janssen
Announces U.S. FDA
Approval of
CABENUVA (rilpivirine and
cabotegravir), the
First Long-Acting
Regimen for the
Treatment of HIV". www.prnewswire...
-
absorption and high bioavailability.
Cabenuva is
approved by FDA as
cabotegravir extended-release
injectable nano-suspension, plus
rilpivirine extended-release...